Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly

Archives of Internal Medicine

Volumn 163, Issue 4, 2003, Pages 481-486

  Mamdani, Muhammad ^a   Rochon, Paula ^b   Juurlink, David N ^b   Anderson, Geoffrey M ^b   Kopp, Alex ^b   Naglie, Gary ^b   Austin, Peter C ^b   Laupacis, Andreas ^b  

^a INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; ANTIRHEUMATIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CELECOXIB; CLONIDINE; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; ESTROGEN; GUANETHIDINE; HYDRALAZINE; IBUPROFEN; LOOP DIURETIC AGENT; METHYLDOPA; MINOXIDIL; MISOPROSTOL; NAPROXEN; NITRATE; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB; UNINDEXED DRUG;

ACUTE HEART INFARCTION; AGED; ARTICLE; CARDIOVASCULAR RISK; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; DRUG USE; FEMALE; HEART PROTECTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NONBIOLOGICAL MODEL; PRIORITY JOURNAL;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CASE-CONTROL STUDIES; CYCLOOXYGENASE INHIBITORS; FEMALE; HUMANS; LACTONES; MALE; MYOCARDIAL INFARCTION; NAPROXEN; ONTARIO; PROPORTIONAL HAZARDS MODELS; PYRAZOLES; RETROSPECTIVE STUDIES; RISK FACTORS; SULFONAMIDES; SULFONES;

EID: 0037463569     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.163.4.481     Document Type: Article

References (21)

1. New arthritis medication achieves fastest adoption ever recorded in Canada. IMS Health Canada Web site. September 9, 1999. Available at: http://www.imshealthcanada.com/htmen/4_2_1_15 htm. Accessed December 5, 2002.
2. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000;343:1520-1528
3. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001;286:954-959.
4. Reicin AS, Shapiro D, Sperling RS, Barr E, Yu Q. Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone). Am J Cardiol. 2002;89:204-209.
5. White WB, Faich G, Whelton A, et al. Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. Am J Cardiol. 2002;89:425-430.
6. Ray WA, Stein MC, Hall K, Daugherty JR, Griffin MR. Non-steroidal antiinflammatory drugs and the risk of serious coronary heart disease: an observational cohort study. Lancet, 2002;359:118-123.
7. Rahme E, Pilote L, LeLorier J. Association between naproxen use and protection against acute myocardial infarction. Arch Intern Med. 2002;162:1111-1115.
8. Jick SS. The risk of gastrointestinal bleed, myocardial infarction, and newly diagnosed hypertension in users of meloxicam, diclofenac, naproxen, and piroxicam. Pharmacotherapy. 2000;20:741-744.
9. Watson DJ, Rhodes T, Cai B, Guess HA. Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch Intern Med. 2002;162:1105-1110.
10. Solomon DH, Glynn RJ, Levin R, Avorn J. Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch Intern Med. 2002;162:1099-1104.
11. Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast PG, Griffin MR. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet. 2002;360:1071-1073.
12. Austin PC, Daly P, Tu JV. A multicenter study of the coding accuracy of hospital discharge administrative data for patients admitted to cardiac care units in Ontario. Am Heart J. 2002;144:290-296.
13. Cox JL, Melady MP, Chen E, Naylor CD. Towards improved coding of acute myocardial infarction in hospital discharge abstracts: a pilot project. Can J Cardiol. 1997;13:351-358.
14. Schneeweiss S, Seeger JD, Maclure M, Wang PS, Avorn J, Glynn RJ. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol. 2001;154:854-864.
15. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.
16. Lassila HC, Stoehr GP, Ganguli M, et al. Use of prescription medications in an elderly rural population: the MoVIES Project. Ann Pharmacother. 1996;30:589-595.
17. Wolinsky FD, Wyrwich KW, Jung SC, Gurney JG. The risk of hospitalization for acute myocardial infarction among older adults. J Gerontol A Biol Sci Med Sci. 1999;54:M254-M261.
18. FitzGerald GA. Cardiovascular pharmacology of nonselective nonsteroidal antiinflammatory drugs and coxibs: clinical considerations. Am J Cardiol. 2002; 89(6, suppl 1):26D-32D.
19. Van Hecken A, Schwartz JI, Depre M, et al. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol. 2000;40:1109-1120.
20. Basinski ASH. Hospitalization for cardiovascular medical diagnoses. In: Naylor CD, Slaughter P, eds. Cardiovascular Health and Services in Ontario: An ICES Atlas. Toronto, Ontario: Continental Press; 1999:15-50.
21. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001;345:1809-1817.